(PDF) P3.01-106 Real-World Data to Evaluate the Clinical

P3.01-106 Real-World Data to Evaluate the Clinical Benefit of NGS for Directing Lung Adenocarcinoma Treatment

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1667

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Analysis of Real World Data to Evaluate Survival Benefit of Radiation Therapy in Stage III / N2 Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English

Pcp53 - A Diagnostic Framework to Evaluate Real-World Data Sources for Real-World Evidence Generation

Value in Health

Occupational Health

English

P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data

Journal of Thoracic Oncology

Respiratory Medicine

English

Real-World Data on Nivolumab Treatment of Non-Small Cell Lung Cancer

Acta Oncologica

Nuclear Medicine

English

Limited Data to Evaluate Real‐World Effectiveness of Enzyme Replacement Therapy for Mucopolysaccharidosis Type I

Journal of Inherited Metabolic Disease

English

MS26.02 Translation of Clinical Data to Real World - North America

Journal of Thoracic Oncology

Respiratory Medicine

English

Less Biased Estimation of the Survival Benefit of Carotid Endarterectomy Using Real-World Data

JAMA network open

English

P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients With Metastatic Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-47 Clinical Characteristics and Outcome for Patients With Advanced Lung Adenocarcinoma Treated With First-Line Pemetrexed Plus Platinum

Journal of Thoracic Oncology

Respiratory Medicine

English